Cascadian Therapeutics Receives a Hold from Cantor Fitzgerald

By Carrie Williams

Cantor Fitzgerald analyst Mara Goldstein assigned a Hold rating to Cascadian Therapeutics (NASDAQ: CASC) today and set a price target of $4. The company’s shares closed yesterday at $3.61, close to its 52-week high of $10.98.

According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -3.5% and a 41.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Karyopharm Therapeutics.

Cascadian Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one year high of $10.98 and a one year low of $3.18. Currently, Cascadian Therapeutics has an average volume of 326.9K.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CASC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor.